This post was just published on ZYX Buy Change Alert.
FOLD plans to submit a new drug application to FDA for the oral precision medicine migalastat for Fabry disease. The stock is jumping on the news.
We are not recommending buying FOLD here but it can be part of a basket on a pullback as discussed below.
Based on questions you are asking us, we are republishing the prior post here:
INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIA BUYOUT
For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage.
Previously our subscribers benefited handsomely from buyout of MDVN. MDVN was long from $55.50 and the stock was tendered at $81.50 producing an annualized return of 149%. In the wake of MDVN buyout, we published a post INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MDVN BUYOUT .
ARIA was on the top of that list and now it has produced 237% gain for some of our subscribers. The following seven stocks still remain prime buyout targets.
All of these seven companies that are not in the portfolio are on our radar. We are likely to issue official buy signals with buy zones, target zones and stop zones in due course when our strict criteria is met.
In the interim, in response to the last post, some of our sophisticated subscribers already purchased a basket of these stocks. Sophisticated subscribers who are aggressive may consider purchasing a basket of these seven stocks with small quantities on pullbacks as our stringent criteria to give official signals may not be met.
You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.